![David Balyeat](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
David Balyeat has founded a company called AJNA BioSciences PBC in 2021 and currently holds the title of Vice President-Innovation & Operations.
Cargos activos de David Balyeat
Empresas | Cargo | Inicio |
---|---|---|
Ajna Biosciences Pbc
![]() Ajna Biosciences Pbc Pharmaceuticals: OtherHealth Technology AJNA BioSciences PBC is a botanical drug development company that focuses on natural pharmaceuticals to address mental health and neurological disorders. The company is based in Littleton, CO, and was founded by David Balyeat and Joel Stanley. The company's strategy involves selecting plant and fungi species with a well-established history of therapeutic use to streamline drug discovery and mitigate late-stage clinical trial risk. AJNA's unique platform combines specialized laboratory infrastructure and clinical and regulatory expertise for rapid development of investigational new drugs. The company's commercialization strategy is designed for co-development partnerships, IP licensing, and vertically integrated drug products in a broad range of botanical species and clinical indications. AJNA is a public benefit corporation that maximizes profitability and sustainability for both people and the planet. Joel Stanley has been the CEO since incorporation. | Fundador | 01/04/2021 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Ajna Biosciences Pbc
![]() Ajna Biosciences Pbc Pharmaceuticals: OtherHealth Technology AJNA BioSciences PBC is a botanical drug development company that focuses on natural pharmaceuticals to address mental health and neurological disorders. The company is based in Littleton, CO, and was founded by David Balyeat and Joel Stanley. The company's strategy involves selecting plant and fungi species with a well-established history of therapeutic use to streamline drug discovery and mitigate late-stage clinical trial risk. AJNA's unique platform combines specialized laboratory infrastructure and clinical and regulatory expertise for rapid development of investigational new drugs. The company's commercialization strategy is designed for co-development partnerships, IP licensing, and vertically integrated drug products in a broad range of botanical species and clinical indications. AJNA is a public benefit corporation that maximizes profitability and sustainability for both people and the planet. Joel Stanley has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- David Balyeat